Corcept Therapeutics ( (CORT) ) has released its Q1 earnings. Here is a breakdown of the information Corcept Therapeutics presented to its investors.
Corcept Therapeutics, a commercial-stage company focused on developing medications for serious disorders by modulating cortisol, has reported its first-quarter financial results for 2025.
The company announced a revenue of $157.2 million for the first quarter of 2025, marking an increase from $146.8 million in the same period of 2024. Despite this revenue growth, net income per diluted share decreased to $0.17 from $0.25 in the previous year. Corcept’s cash and investments stood at $570.8 million as of March 31, 2025.
Key highlights include the progress in clinical trials, particularly the New Drug Application for relacorilant in hypercortisolism, which is expected to be approved by the end of the year. The company also plans to submit an NDA for relacorilant in platinum-resistant ovarian cancer in the third quarter. Additionally, Corcept is advancing its research in treating ALS and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Looking ahead, Corcept Therapeutics remains optimistic about its growth prospects, reiterating its 2025 revenue guidance of $900 – $950 million. The company continues to focus on expanding its clinical trials and advancing its pipeline of cortisol modulators to address various serious medical conditions.